9. Humulin

Humulin's sales growth measured a substantial 13% in the U.S.

Company: Eli Lilly
2016 U.S. sales: $862 million
Drug class: Human insulin

Eli Lilly’s Humulin has been around for a long, long time, but it’s still pumping out sales growth. In 2016, that sales growth measured a substantial 13% in the U.S.

The reasons? Demand for the Indianapolis drugmaker’s product increased, it said, and that was the primary driver. But Lilly also benefitted from higher net prices, thanks to a change in the estimate of a government rebate in the first quarter of last year.

For a long time, Lilly kept the growth coming with list price increases on its elderly and long-off-patent med. Between 2007 and 2013, Humulin’s price leapt by 354%, offsetting payer pressure and the termination of an agreement with Walmart.

After taking a 17.5% price hike on Humulin in 2015, however, Lilly cut its increase by more than half to 7.5% in 2016, according to Wells Fargo analyst David Maris. And as of late January of this year, the company had yet to take one at all.

9. Humulin

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.